Focused On-demand Library for Regulator of microtubule dynamics protein 3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q96TC7

UPID:

RMD3_HUMAN

Alternative names:

Cerebral protein 10; Protein FAM82A2; Protein FAM82C; Protein tyrosine phosphatase-interacting protein 51; TCPTP-interacting protein 51

Alternative UPACC:

Q96TC7; A9UMZ9; B3KRR3; Q6ZWE9; Q96H23; Q96SD6; Q9H6G1; Q9NVQ6

Background:

Regulator of microtubule dynamics protein 3, known by alternative names such as Cerebral protein 10 and Protein FAM82A2, plays a crucial role in cellular calcium homeostasis regulation. It is implicated in the differentiation and apoptosis of keratinocytes, with overexpression leading to apoptosis. This protein's involvement in microtubule dynamics underscores its importance in cellular structure and function.

Therapeutic significance:

Understanding the role of Regulator of microtubule dynamics protein 3 could open doors to potential therapeutic strategies. Its pivotal role in cellular processes such as calcium homeostasis, differentiation, and apoptosis highlights its potential as a target for therapeutic intervention in diseases where these processes are dysregulated.